BRISBANE, Calif., Dec. 4, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that the company's lead PARP product candidate for triple negative breast cancer, BSI-201, will be the subject of a poster presentation at the 2008 annual San Antonio Breast Cancer Symposium (SABCS). The poster titled "Triple Negative Metastatic Breast Cancer: A Phase 2, Multi-Center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C) With or Without BSI-201, a PARP Inhibitor" will be presented during the SABCS's second poster session in Exhibit Hall B at 7:00 a.m. (CST) on Friday, December 12, 2008 at the Henry B. Gonzalez Convention Center, 200 E. Market Street in San Antonio, Texas.
About SABCS
The CTRC-AACR SABCS is the largest annual symposium in the world devoted to breast cancer research and physician education. The symposium provides an important venue for cancer experts to review the latest information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant disease. This year's program will include lectures and mini-symposia by experts in clinical and basic research, more than 1,000 selected slide and poster presentations chosen from the submitted abstracts, and case discussions. The SABCS will take place on December 10-14, 2008, at the Henry B. Gonzales Convention Center in San Antonio, Texas.
About BiPar Sciences and BSI-201
BiPar Sciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to address unmet needs of cancer patients. The company's lead product candidate is BSI-201, which is in Phase 2 testing for triple negative breast cancer, ovarian cancer and other malignancies. BSI-201 is a poly (ADP-ribose) polymerase (PARP) inhibitor, a targeted approach to treating solid tumors by preventing cancer cells from repairing damaged DNA, ultimately causing the cancer cells to die. The company is also conducting preclinical studies on two additional compounds, BSI-401 (PARP inhibitor) and BSI-302 (anti-tubulin program). BiPar Sciences is privately held with headquarters in Brisbane, California. For more information, please visit www.biparsciences.com.